DDInter416 DDInter228
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease.
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) resembles {v} (Compound) Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Diphenidol {u} (Compound) resembles {v} (Compound) Bepridil
Bepridil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenoxylate
Diphenoxylate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Valproic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarilumab
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenoxylate
Diphenoxylate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Clofedanol
Clofedanol {u} (Compound) resembles {v} (Compound) Bedaquiline
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenoxylate
Diphenoxylate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Bepridil (Compound) and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Diphenoxylate (Compound) and Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Diphenoxylate (Compound) and Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Clofedanol (Compound) and Clofedanol (Compound) resembles Bedaquiline (Compound) and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Diphenoxylate (Compound) and Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine and Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin